A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice

Sponsor
Amgen
Study ID
NCT04031027
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.

Study Details

The DARWIN study is an Italian multicenter, observational, cross-sectional study involving both a primary data collection (at enrollment visit) and secondary use of data (retrospective observation period). DARWIN will describe patients' characteristics in Italian routine clinical practice as well as the medication utilization patterns, including needs and benefits form the patient's perspective.

Key Dates

First listed
Jul 24, 2019
Start date
Jul 22, 2019
Status verified
Mar 2024
Primary completion
Jan 27, 2021
Completion
Jan 27, 2021

Study Design

Enrollment
184 participants (actual)

Primary Outcome Measure

Mean age of the patients treated with apremilast [ Time Frame: At treatment initiation (retrospective analysis, about 6 (+/-1) months prior enrolment) ]

Related Studies